MedTrace Logo

Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation

NCT05262322 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 234

Last updated 2022-07-19

No results posted yet for this study

Summary

National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).

Early evidence suggest that patients with atrial fibrillation (AF) who do not receive anticoagulation are more likely to experience a stroke. However, the characteristics of patients experiencing a first AF-related stroke in real-world settings, who have not been receiving anticoagulation, have not been well documented.

It is unclear how the direct anti-FXa oral anticoagulants have been used within real world practice since the introduction of edoxaban in 2015.

Conditions

Interventions

DRUG

Edoxaban

This was a non-interventional, observational study. No drug was administered in this study.

DRUG

Apixaban

This was a non-interventional, observational study. No drug was administered in this study.

DRUG

Rivaroxaban

This was a non-interventional, observational study. No drug was administered in this study.

Sponsors & Collaborators

  • Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company

    lead INDUSTRY

Principal Investigators

  • Global Clinical Leader · Daiichi Sankyo

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-02-15
Primary Completion
2021-07-09
Completion
2021-07-09

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05262322 on ClinicalTrials.gov